ABIO - מחיר רכישת החברה arcabio.com

The biologics market for heart treatment possesses colossal potential, as evidenced by the active recruitment of volunteers for final-stage testing. In this segment, ARCA Biopharma (ABIO) is developing precision cardiology by combining diagnostics with targeted therapy. This chart illustrates the company's valuation dynamics, which currently stand at . Growth prospects are tied to the deal with Oruka, a pivot into profitable dermatology, and the absence of debt.

For the biotech sector company ARCA Biopharma (ABIO), which depends on clinical trial outcomes in the absence of operating profit, the assessment of liquidity and debt load is critical. This metric aggregates market capitalization and net debt to determine the actual cost of business acquisition, allowing the total capital indicator to assess the real value of the asset excluding temporary cash reserves.